Metabolic-bariatric surgery (MBS) has been shown to lower the risk of pancreatic cancer in people with obesity, especially in those with type 2 diabetes (T2D). A meta-analysis of over 3.7 million adults with obesity found that those who underwent MBS had a significantly lower risk of pancreatic cancer compared to those who did not have the surgery. The findings suggest that MBS has the potential to reduce pancreatic cancer risk, particularly in high-risk populations with obesity and T2D. However, further research is needed to confirm the protective role of MBS in pancreatic cancer development and explore its effects on other obesity and T2D-related cancers.
Source link